|
|
 |
|
 |
|
|
|
|
Title:
|
Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients with Metastatic Colorectal Cancer - IRB# 09-045A
|
|
Treatments:
|
Calcium aluminosilicate anti-diarrheal
|
|
Disease Site:
|
Cancer control
|
|
Disease SubSite:
|
Anti-diarrheal
|
|
Drug Provided:
|
Calcium aluminosilicate anti-diarrheal
|
|
Comments:
|
|
|
Eligibility:
|
Diagnosis of colorectal cancer, Metastatic disease, Scheduled to receive irinotecan hydrochloride alone or in combination with fluorouracil and/or biological therapy (e.g., cetuximab). No uncontrolled brain metastasis. Previously treated brain metastasis allowed. Prior/Concurrent Therapy: See Disease Characteristics, Prior treatment for metastatic disease allowed, More than 4 weeks since prior chemotherapy, More than 4 weeks since prior radiotherapy, No concurrent radiotherapy, No concurrent medication schedule that does not permit a 2-hour window between administration of calcium aluminosilicate anti-diarrheal (CASAD) and other medications.
|
|
Participating Sites:
|
Adventist Medical Center, Northwest Cancer Specialists, Providence Milwaukie Hospital, Providence Portland Medical Center, Providence St. Vincent Medical Center, Southwest Washington Medical Center
|
|
|
|
|
 |
|
 |
|
|
|